Merck & Co., Inc. (MRK) Quick Ratio
- Quick ratio · latest quarter: Value 0.71×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 0.71× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $19.70B ÷ $27.73B ≈ 0.71× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 19.70B USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 27.73B USD | Liabilities, Current |
| Cash and equivalents | 6.85B USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 292.00M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | 12.56B USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 6.21B USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $19.70B | $27.73B | $6.85B | $292.00M | $12.56B | $6.21B | 0.71× |
| 2026-03-31 | $17.91B | $26.95B | $5.33B | $375.00M | $12.21B | $6.48B | 0.66× |
| 2025-12-31 | $26.34B | $28.33B | $14.56B | $0.00 | $11.78B | $6.66B | 0.93× |
| 2025-09-30 | $30.33B | $28.63B | $18.17B | $45.00M | $12.12B | $6.44B | 1.06× |
| 2025-06-30 | $20.47B | $26.04B | $8.01B | $615.00M | $11.85B | $6.60B | 0.79× |
| 2025-03-31 | $20.02B | $25.17B | $8.63B | $599.00M | $10.79B | $6.20B | 0.80× |
| 2024-12-31 | $23.97B | $28.42B | $13.24B | $447.00M | $10.28B | $6.11B | 0.84× |
| 2024-09-30 | $25.97B | $29.59B | $14.59B | $0.00 | $11.38B | $6.24B | 0.88× |
| 2024-06-30 | $23.00B | $26.06B | $11.30B | $50.00M | $11.64B | $6.47B | 0.88× |
| 2024-03-31 | $16.98B | $25.10B | $5.58B | $40.00M | $11.37B | $6.51B | 0.68× |
| 2023-12-31 | $17.44B | $25.69B | $6.84B | $252.00M | $10.35B | $6.36B | 0.68× |
| 2023-09-30 | $19.17B | $23.09B | $8.61B | $168.00M | $10.39B | $6.13B | 0.83× |
| 2023-06-30 | (m) | $23.39B | $5.66B | (m) | $11.03B | $5.93B | (m) |
| 2023-03-31 | (m) | $23.13B | $9.71B | (m) | $10.41B | $5.86B | (m) |
| 2022-12-31 | (m) | $24.24B | $12.69B | (m) | $9.45B | $5.91B | (m) |
| 2022-09-30 | (m) | $23.00B | $11.14B | (m) | $9.48B | $5.61B | (m) |
| 2022-06-30 | (m) | $23.17B | $9.68B | (m) | $9.64B | $5.54B | (m) |
| 2022-03-31 | (m) | $22.32B | $8.56B | (m) | $9.83B | $5.77B | (m) |
| 2021-12-31 | (m) | $23.87B | $8.10B | (m) | $9.23B | $5.95B | (m) |
| 2021-09-30 | (m) | $23.73B | $10.02B | (m) | $8.57B | $5.60B | (m) |
| 2021-06-30 | (m) | $21.91B | $8.57B | (m) | $7.84B | $5.50B | (m) |
| 2021-03-31 | (m) | $26.36B | $6.98B | (m) | $8.23B | $6.40B | (m) |
| 2020-12-31 | $15.91B | $27.33B | $8.06B | $0.00 | $7.85B | $6.31B | 0.58× |
| 2020-09-30 | $15.78B | $20.41B | $7.36B | $0.00 | $8.42B | $6.13B | 0.77× |
| 2020-06-30 | $18.68B | $22.18B | $11.10B | $0.00 | $7.58B | $6.06B | 0.84× |
| 2020-03-31 | $15.61B | $23.48B | $7.42B | $7.00M | $8.18B | $5.85B | 0.66× |
| 2019-12-31 | $17.23B | $22.22B | $9.68B | $774.00M | $6.78B | $5.98B | 0.78× |
| 2019-09-30 | $16.46B | $20.68B | $7.87B | $149.00M | $8.44B | $5.86B | 0.80× |
| 2019-06-30 | $15.07B | $20.09B | $6.66B | $446.00M | $7.96B | $5.85B | 0.75× |
| 2019-03-31 | $16.41B | $18.54B | $8.08B | $722.00M | $7.61B | $5.71B | 0.88× |
| 2018-12-31 | $15.94B | $22.21B | $7.96B | $899.00M | $7.07B | $5.44B | 0.72× |
| 2018-09-30 | $17.66B | $18.59B | $7.83B | $2.46B | $7.37B | $5.42B | 0.95× |
| 2018-06-30 | $14.88B | $18.13B | $5.31B | $2.28B | $7.29B | $5.18B | 0.82× |
| 2018-03-31 | $14.59B | $16.96B | $4.48B | $2.86B | $7.25B | $5.38B | 0.86× |
| 2017-12-31 | $15.37B | $18.61B | $6.09B | $2.41B | $6.87B | $5.10B | 0.83× |
| 2017-09-30 | $18.87B | $19.47B | $7.90B | $3.29B | $7.67B | $5.26B | 0.97× |
| 2017-06-30 | $19.41B | $18.76B | $7.79B | $4.18B | $7.44B | $5.41B | 1.03× |
| 2017-03-31 | $22.32B | $19.82B | $11.71B | $3.54B | $7.07B | $5.15B | 1.13× |
| 2016-12-31 | $21.36B | $17.20B | $6.51B | $7.83B | $7.02B | $4.87B | 1.24× |
| 2016-09-30 | $20.43B | $15.55B | $7.91B | $5.16B | $7.36B | $5.24B | 1.31× |
| 2016-06-30 | $18.75B | $14.92B | $6.61B | $5.23B | $6.92B | $5.25B | 1.26× |
| 2016-03-31 | $19.79B | $17.57B | $9.72B | $3.23B | $6.85B | $5.10B | 1.13× |
| 2015-12-31 | $19.91B | $19.20B | $8.52B | $4.90B | $6.48B | $4.70B | 1.04× |
| 2015-09-30 | $18.50B | $17.58B | $7.55B | $4.54B | $6.41B | $5.12B | 1.05× |
| 2015-06-30 | $17.88B | $17.51B | $6.92B | $4.45B | $6.51B | $5.31B | 1.02× |
| 2015-03-31 | $22.27B | $20.44B | $7.98B | $7.62B | $6.67B | $5.54B | 1.09× |
| 2014-12-31 | $22.34B | $18.77B | $7.44B | $8.28B | $6.63B | $5.57B | 1.19× |
| 2014-09-30 | $20.86B | $25.93B | $11.37B | $2.98B | $6.51B | $5.82B | 0.80× |
| 2014-06-30 | $20.42B | $17.93B | $9.74B | $3.65B | $7.02B | $6.14B | 1.14× |
| 2014-03-31 | $27.70B | $22.47B | $15.83B | $4.68B | $7.19B | $6.38B | 1.23× |
| 2013-12-31 | $24.67B | $17.87B | $15.62B | $1.86B | $7.18B | $6.23B | 1.38× |
| 2013-09-30 | $25.75B | $18.21B | $14.09B | $4.08B | $7.58B | $6.74B | 1.41× |
| 2013-06-30 | $25.88B | $18.40B | $15.09B | $3.01B | $7.78B | $6.77B | 1.41× |
| 2013-03-31 | $23.99B | $18.80B | $13.02B | $3.00B | $7.96B | $6.77B | 1.28× |
| 2012-12-31 | $23.81B | $18.35B | $13.45B | $2.69B | $7.67B | $6.54B | 1.30× |
| 2012-09-30 | $26.07B | $15.58B | $17.36B | $757.00M | $7.95B | $6.73B | 1.67× |
| 2012-06-30 | $25.60B | $16.91B | $16.75B | $698.00M | $8.15B | $6.25B | 1.51× |
| 2012-03-31 | $24.29B | $16.58B | $14.66B | $910.00M | $8.73B | $6.34B | 1.46× |
| 2011-12-31 | $23.23B | $16.25B | $13.53B | $1.44B | $8.26B | $6.25B | 1.43× |
| 2011-09-30 | $23.71B | $16.59B | $14.25B | $1.32B | $8.14B | $6.24B | 1.43× |
| 2011-06-30 | $22.46B | $15.76B | $12.34B | $1.64B | $8.47B | $6.22B | 1.42× |
| 2011-03-31 | (m) | $15.66B | $11.70B | $1.33B | (m) | $6.06B | (m) |
| 2010-12-31 | (m) | $15.64B | $10.90B | $1.30B | (m) | $5.87B | (m) |
| 2010-09-30 | (m) | $17.32B | $9.87B | $750.40M | (m) | $6.26B | (m) |
| 2010-06-30 | (m) | $15.42B | $8.67B | $1.28B | (m) | $6.24B | (m) |
| 2010-03-31 | (m) | $16.46B | $8.24B | $1.54B | (m) | $6.83B | (m) |
| 2009-12-31 | (m) | $15.75B | $9.31B | $293.10M | (m) | $8.06B | (m) |
| 2009-09-30 | (m) | $5.09B | $4.31B | (m) | $3.13B | $3.46B | (m) |
| 2009-06-30 | (m) | $5.19B | $2.99B | (m) | $3.16B | $3.48B | (m) |
| 2009-03-31 | (m) | (m) | $6.02B | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | $5.19B | $3.37B | (m) | $2.82B | $3.11B | (m) |
| 2008-09-30 | (m) | (m) | $3.16B | (m) | (m) | (m) | (m) |
| 2008-06-30 | (m) | (m) | $2.71B | (m) | (m) | (m) | (m) |
| 2007-12-31 | (m) | (m) | $2.28B | (m) | (m) | (m) | (m) |
| 2006-12-31 | (m) | (m) | $5.91B | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |